Glenmark launches SUTIB (Sunitinib) –priced 96% lower than the innovator brand
Oral capsules, highly affordable at Rs. 7000 (50 mg), Rs. 3600 (25 mg) and Rs….
Group Vice President & Business Head
Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type2 diabetes in India
Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination…